About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, November 5th, 2012

The QualityStocks
Daily Stock List


United Silver Corp. (USC.TO)

Today we are highlighting United Silver Corp. (USC.TO), here at the QualityStocks Daily Newsletter.

Listed on the Toronto Stock Exchange, United Silver Corp. owns an 80 percent interest in the Crescent Silver Mine in Idaho's prolific Silver Belt. The Company's dedication is to building a senior silver-producing mining company based on aggressive exploration and development of the highly prospective current land position at the Crescent Silver Mine project and through the acquisition of additional precious metals interests. United Silver has their headquarters in Kellogg, Idaho. The Company's shares also trade on the OTC Pink Current Information.

The Crescent Silver Mine in Idaho's Silver Belt is directly between two of the world's historically largest silver producing properties, the Sunshine and Bunker Hill mines. In addition, United Silver offers a complete portfolio of mining services. These include contract mining, mine machine repair, as well as fabrication services to silver miners in the district.

This past August, United Silver announced that the Board of Directors approved a revision and new emphasis of exploration and development priorities at the Crescent Mine, located near the town of Kellogg, in the Coeur d'Alene Silver Belt. Jointly, the Crescent Mine, along with the neighboring Sunshine and Bunker Hill mines, historically produced over 550 million ounces of silver.

The Crescent remains largely unexplored to depth and along strike of United Silver's 3,500-meter ownership of the South Vein and the Alhambra Vein. Earlier drifting on the South Vein from the spiral decline returned face samples yielding up to 188 ounces per ton silver, among the highest values from panel sampling of the advancing face so far encountered. This opens up new territory for exploratory drifting to test the down-rake extent of the shoot.

United Silver has a Joint Venture (JV) with the New Jersey Mining Company to mill the Crescent Mine's ore. Mine Fabrication and Machine, a business unit of the Company's wholly owned subsidiary, United Mine Services, Inc., is performing much of the mill construction. The JV agreement gives the Company an exclusive right to 7,000 tonnes per month of milling capacity, with first rights on additional unused capacity. The mill is situated less than four miles from the Crescent Mine.

United Silver Corp. (USC.TO), closed Monday's trading session at $0.26, up 6.12%, on 64,500 volume. The stock's 52-week low/high is $0.15/$0.47.

Centrue Financial Corp. (TRUE)

Today we are reporting on Centrue Financial Corp. (TRUE), here at the QualityStocks Daily Newsletter.

Centrue Financial Corp. is a regional financial services company with headquarters in St. Louis, Missouri. Incorporated in Delaware in 1982, they operate as the holding company for Centrue Bank. The Bank provides commercial and retail banking services to consumer, commercial and industrial, and public or governmental customers in western and southern suburbs of the Chicago metropolitan area, Central Illinois, as well as the metropolitan St. Louis area. Centrue Financial lists on the OTCQB.

The Company provides a complete array of banking services. Their Centrue Bank engages in commercial and retail banking and offers a wide spectrum of lending, depository, and related financial services, including accepting deposits; commercial and industrial, consumer, and real estate lending; trust and asset management services. They additionally offer other banking services tailored for consumer, commercial and industrial, and public or governmental customers

Centrue has 26 locations; the Company has total assets of approximately $1 billion, total loans of $700 million, and total deposits of $900 million.

In August, Centrue Financial announced their 2012 Second Quarter earnings. Second quarter of 2012 net income was $0.1 million. This is in comparison to a $0.5 million net loss for the first quarter of 2012 and a $2.4 million net loss in the second quarter of 2011. Their principal subsidiary, Centrue Bank, posted net income of $0.5 million for the second quarter 2012. This is compared to net income of $0.03 million for the first quarter of 2012 and a net loss of $2.0 million for the second quarter of 2011.

Nonperforming assets declined $9.7 million, or 12.5 percent, from first quarter 2012 and $19.8 million, or 22.6 percent, from June 30, 2011. Centrue Bank remains "Well Capitalized" at the end of the second quarter of 2012.

For the first six months of 2012, the Company reported a net loss of $0.4 million, or ($0.24) per common diluted share. This is compared to a net loss of $5.9 million, or ($1.14) per common diluted share, for the same period in 2011.

Centrue Financial Corp. (TRUE), closed Monday's trading session at $0.40, even for the day. The average volume for the last 60 days is 4,216 and the stock's 52-week low/high is $0.15/$0.88.

Asia Green Agriculture Corp. (AGAC)

We are reporting on Asia Green Agriculture Corp. (AGAC), here at the QualityStocks Daily Newsletter.

Asia Green Agriculture Corp. is a green and organic food company that lists on the OTC Markets: OTCQB. Currently, the Company provides more than 100 kinds of fresh and processed products in three principal categories. These categories are bamboo shoot products, fresh vegetables and fruit, and processed vegetables. Asia Green Agriculture has a vertically integrated operation consisting of planting, manufacturing and sales of final products. Asia Green has their corporate headquarters in Fujian Province, China.

The Company can supply most of the fresh raw materials for their products from their own land. In August of this year, Asia Green reported that they anticipate making capital expenditures over the next six to eighteen months to increase their cold storage capacity, and increase planting bases and processing capacity.

Asia Green Agriculture conducts their operations in China. The Company has no immediate plans to expand their global sales presence beyond China and Japan. They sell products in 10 provinces and administrative regions in China as well as in the Japanese market. They garnered approximately 93 percent and 7 percent of their revenue in the People's Republic of China (PRC) and in Japan, respectively, in 2011, and approximately 95 percent and 5 percent in the PRC and in Japan, respectively, in the first six months of 2012.

Bamboo shoot products accounted for approximately 48 percent of the Company's revenue in 2011. Fresh vegetables and fruit accounted for approximately 29 percent of revenue, processed vegetables for 8 percent of revenue, and bamboo wood for 15 percent of revenue, respectively. In the six months ended June 30, 2012, bamboo shoot products accounted for approximately 73 percent of Asia Green's revenue. Fresh vegetables and fruits accounted for approximately 17 percent, processed vegetables for 3 percent, and bamboo wood for 7 percent.

Currently, the Company sells through distributors and members of their sales force to farmers' markets, supermarkets, food manufacturers, restaurants and retailers in China. They had an internal sales team of approximately 50 members and more than 200 distributors as of June 30, 2012. During the remainder of 2012, the Company plans to continue expansion of their sales network domestically.

Asia Green has a 6,000 metric ton cold storage facility as of June 30, 2012. This is for storing fresh and semi-finished products. They are adding an additional 5,500 metric ton cold storage facility to meet the requirements of their existing products and the anticipated need for storage because of their recent new product launches. As of June 30, 2012, the construction work for this additional facility continues to take place.

Asia Green Agriculture Corp. (AGAC), closed Monday's trading session at $0.58, up 58.90%, on 2,500 volume with 2 trades. The average volume for the last 60 days is 3,008 and the stock's 52-week low/high is $0.26/$5.00.

Remark Media, Inc. (MARK)

SmarTrend Newsletters reported earlier on Remark Media, Inc.(MARK), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Founded in 2007, Remark Media, Inc. is a global digital media company whose shares trade on the NASDAQ Capital Market. The Company focuses on creating destinations that merge engaging content with rich social interaction. Remark Media has their headquarters in Atlanta, Georgia. The Company has additional operations in New York, Beijing, China, and Sao Paulo, Brazil. The Company previously went by the name HSW International, Inc. They changed their name to Remark Media, Inc. in January 2012.

The Company develops and operates next-generation web publishing platforms combining traditional web publishing with social media. Remark Media owns and operates a portfolio of digital brands in the personal finance space. These include DimeSpring.com, Banks.com, IRS.com and FileLater.com.

In addition, Remark Media is a founding partner and developer of Sharecare, a highly searchable social Question & Answer healthcare platform organizing and answering health and wellness questions. Sharecare is jointly owned by Remark Media, Dr. Mehmet Oz, Harpo Productions, Discovery Communications, Sony Pictures Television and Jeff Arnold.

Remark Media is the exclusive digital publisher in China and Brazil for translated content from HowStuffWorks.com, a subsidiary of Discovery Communications. BoWenWang (bowenwang.com.cn) and ComoTudoFunciona (hsw.com.br) provide readers in China and Brazil with thousands of articles about how the world around them works, serving as destinations for credible, easy-to-understand reference information.

Today, Remark Media announced the launch of Dimespring.com, created to deliver actionable personal finance advice. Previously in beta, the website also serves as the nucleus for a larger financial ecosystem that includes the newly designed Banks.com and IRS.com. The websites incorporate responsive design, providing an optimized experience across mobile and tablet screens.

Dimespring.com will connect visitors to actionable content and a diverse community of personal finance experts from leading organizations such as The Garrett Planning Network and The National Association of Personal Finance Advisers (NAPFA). Moreover, consumers will be able to share their personal finance experiences with the Dimespring community and learn from others like them. Dimespring.com will offer interactive sessions with leading financial experts - all free.

Remark Media, Inc. (MARK), closed Monday's trading session at $1.03, up 7.29%, on 10,328 volume with 14 trades. The average volume for the last 60 days is 4,055 and the stock's 52-week low/high is $0.9411/$7.51.

Strata Oil & Gas, Inc. (SOIGF)

AllPennyStocks reported previously on Strata Oil & Gas, Inc. (SOIGF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Founded in 1998, Strata Oil & Gas, Inc. engages in the exploration and development of bitumen from carbonates in Alberta. The Company is focusing on high-value carbonate-hosted bitumen deposits in North America. Their emphasis is on full-cycle exploration. Strata Oil & Gas believes that they can have a greater impact by developing their own exploration projects rather than acquiring advanced projects from others. Strata Oil & Gas has their corporate headquarters in Calgary, Alberta. The Company's shares trade on the OTC Bulletin Board.

At present, Strata Oil & Gas holds a 100 percent interest in 52,480 acres (approximately 82 sections) of oil sands leases in the Peace River region of Alberta's Carbonate Triangle. The Company's Cadotte project has undergone independent evaluation, with a contingent resource of 517 million recoverable barrels and a net present value of $1.3 billion.  

Concerning their development & production plan, Strata is going ahead with a $250 million five phase capital plan to produce 56,000 bbls per day by 2017. Phase 1 is underway with engineering, exploration and pre-production development of the Cadotte holdings.

The Company also has an additional 1,280 acres (2 sections) in the Wabasca region. The estimation is that this region contains greater than 94 billion barrels of oil (Alberta Department of Energy, Cold Heavy Oil Production With Sand In The Canadian Heavy Oil Industry, Dr. Maurice Dusseault, March 2002).

This past August, Strata Oil & Gas announced the appointment of Dr. Michael J. Ranger to the Company's Board of Directors. Dr. Ranger is a well-respected expert in the petroleum industry with a prolific career providing services to a variety of the globe's largest oil companies.

Currently, he is an independent petroleum consultant and is a Director of Canadex Resources Ltd. Before this, he served on the Scientific Advisory Board of Gushor, Inc. from 2007 to 2009, and as a senior geologist at Gulf Canada Resources between 1977 and 1985.

Strata Oil & Gas, Inc. (SOIGF), closed Monday's trading session at $0.15, up 14.50%, on 32,770 volume with 10 trades. The average volume for the last 60 days is 8,882 and the stock's 52-week low/high is $0.05/$0.17.

Tara Minerals Corp. (TARM)

SmallCapVoice and Investor Ideas reported previously on Tara Minerals Corp. (TARM), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Tara Minerals Corp. is focusing on advancing their gold/silver/zinc/lead Don Roman mine and mill and their iron ore projects, all located in Mexico. The Company is deploying their capital to advance their projects by enhancing resources, further outlining new discoveries/targets, as well as acquiring additional strategic assets. Tara Minerals' shares trade on the OTC Bulletin Board. The Company has their headquarters in Henderson, Nevada.

Tara Minerals is positioned to generate significant cash from the sale of Silver, Zinc, and Lead concentrate from their producing Don Roman mine and mill, located in Choix, Mexico. The 25,400 acres Don Roman project, acquired in 2006, consists of an extensive area of hydrothermal alteration that hosts a number of base and precious metal occurrences along the western part of the Northern Sierra Madre Gold Belt. The property lies 15 km SW of the historically prolific La Reforma Pb-Zn-Ag District that is now the focus of concerted exploration by Peñoles. The concessions contain gold/zinc/lead/silver mineralization.  

Tara Minerals has the right to mine the 150-hectare Champinon iron ore property located in Mexico. The host structure has been estimated, through surface mapping and sampling, to be at least 40 m wide, 1.5 km in length and open in all directions. Surface grab samples returned assays ranging from 62.0 percent to 68.9 percent iron ore. The Company has committed to extract and sell a minimum of 60,000 tons every 6 months. The property is 12 km from the Don Roman mill in the Municipality of Choix, State of Sinaloa, Mexico.

In June of this year, Tara Minerals announced that they acquired 100 percent of the title to the Champinon iron ore property in Mexico for $2,175,000 plus any applicable Added Value Tax. Owning Champinon 100 percent gives Tara's team the opportunity to manage future work programs and their costs better.

In September 2012, Tara Minerals announced that the Champinon iron ore project continues to progress towards production. The majority of concrete foundation work, equipment pads, and roadwork have been completed. Furthermore, processing equipment necessary to produce commercial grade iron ore started to arrive at the site.

Tara Minerals Corp. (TARM), closed Monday at $0.5799, up 5.44%, on 30,075 volume with 15 trades. The average volume for the last 60 days is 23,543 and the stock's 52-week low/high is $0.45/$1.08.

Bioheart, Inc. (BHRT)

Investor News Source, AwesomePennyPicks, Vantage Wire, AwesomePennyStocks, and PennyTrader Publisher reported earlier on Bioheart, Inc. (BHRT), and we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, Bioheart, Inc. is an enterprise that operates within the cardiovascular sector of the cell technology industry. The Company delivers cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations. Founded in 1999, Bioheart is based in Sunrise, Florida.

As pertains to biotechnology, the Company focuses on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Their leading product is MyoCell®. This is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for improving cardiac function in chronic heart failure patients.

The MyoCell® muscle stem cell therapy procedure involves a physician removing a small amount of muscle from the patient's thigh. From this muscle specimen, muscle stem cells (also called myoblasts) are then isolated, expanded using Bioheart's proprietary cell-culturing process, and injected directly into the scar tissue of the patient's heart. The cells are delivered by an endoventricular needle-injection catheter during a minimally invasive procedure performed by an interventional cardiologist or vascular surgeon. The muscle stem cells populate the regions of scar tissue. They are intended to improve cardiac function by helping the heart muscle beat more efficiently.

In addition to MyoCell®, Bioheart has a number of cell therapies and related devices for the treatment of chronic and acute heart damage in various stages of development. In addition, the Company has acquired the rights to use certain devices for the treatment of heart damage.

Last week, Bioheart announced that they would initiate their ANGEL trial in Mexico at the Hospital Angeles with the Regenerative Medicine Institute (RMI). NorthStar Biotech LLC, a consortium of Bioheart Directors and Shareholders, agreed to fund the trial. The trial will test the safety and efficacy of LipiCell™ (adipose derived stem cells) in congestive heart failure patients. The first cohort of five patients will be completed and analyzed to help establish a safety profile and preliminary efficacy. Bioheart's intention is to complete a portion of their clinical trials in Mexico to help reduce costs and accelerate the opportunities for commercialization outside the United States.

Bioheart, Inc. (BHRT), closed Monday's trading session at $0.0192, down 4.00%, on 2,333,256 volume with 37 trades. The average volume for the last 60 days is 898,685 and the stock's 52-week low/high is $0.012/$0.082.

Nighthawk Gold Corp. (NHK.V)

We are highlighting Nighthawk Gold Corp. (NHK.V), here at the QualityStocks Daily Newsletter.

Nighthawk Gold Corp. is an exploration company whose shares trade on the TSX Venture Exchange. The Company is concentrating on acquiring and developing gold mineral properties in the Northwest Territories (NWT).  Their land position covers 222,203 acres or 900 square kilometers in the Indin Lake Gold Camp, located approximately 220 kilometers north of Yellowknife, NWT. Nighthawk Gold is based in Toronto, Ontario.

The Company's 2012 diamond drilling program started in March. Their objective is to grow their regional presence in the NWT by way of staking and acquisitions. This is while actively drilling their diverse gold targets to expand and upgrade their gold resource. Nighthawk Gold has an NI 43-101 compliant Inferred Mineral Resource estimate of 42.65 million tonnes with an average grade of 1.05 g/t Au for 1.446 million oz gold using a cut-off grade of 0.6 g/t gold.

The Colomac Gold Project lies within the central portion of Nighthawk Gold's Indin Lake Gold Property. The Company has secured a contiguous land position fully surrounding the Colomac Gold Project by consolidating more than 90 percent of the Indin Lake Greenstone Belt including the related Indin Lake Gold Camp.

The Colomac Gold Project contains at least five separate gold deposits open in all dimensions - Colomac Dyke, Grizzly Bear, Goldcrest, Dyke Lake, and 24/27 - only one of which, the Colomac Dyke Deposit, was historically mined. The currently defined Colomac Gold Project mineralized zones are considered low-grade bulk tonnage style deposits.

Last month, Nighthawk Gold reported results from the final four drill holes of their summer 2012 drill program at their Colomac Gold Property. At  Zone 3.0 (2.0 kilometers south of Zone 2.0), Hole C12-14C intersected 6.75 meters of 13.24 g/t gold, including 1.10 meters of 80.13 g/t gold.

At Zone 3.5 (2.5 kilometers south of Zone 2.0), Hole C12-15 intersected 203.40 meters of 2.49 g/t gold, including 69.35 meters of 4.12 g/t gold, 25.75 meters of 7.78 g/t gold and 13.25 metres of 11.48 g/t gold. It also intersected 15.50 metres of 2.98 g/t gold, including 2.25 metres of 11.67 g/t gold; 33.85 meters of 3.03 g/t gold, including 5.25 meters of 6.69 g/t gold, and 8.30 meters of 3.86 g/t gold.

Hole C12-15 intersected many veins/stringers within Zone 3.5.  Reported average grades (some returning bonanza grade intersections) are much higher than those of previously drilled holes. The Company indicated that drilling at other orientations, in association with the predominant east-west drill orientation employed so far, may result in a significant improvement to the resource.

Nighthawk Gold Corp. (NHK.V), closed Monday's trading at $0.115, down 8.00%, on 187,500 volume. The stock's 52-week low/high is $0.11/$0.41.


The QualityStocks
Company Corner


International Stem Cell Corp. (ISCO)

The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.24, up 4.35%, on 30,350 volume with 14 trades. The stock’s average daily volume over the past 60 days is 109,178, and its 52-week low/high is $0.21/$0.69.

International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.

A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.

In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer

International Stem Cell Corp. Company Blog

International Stem Cell Corp. News:

International Stem Cell Corp's Lifeline Cell Technology Products to Be Added to Fisher Scientific's Catalogs

International Stem Cell Corp Discusses Its New Cellular Reprogramming Technology in View of the Recent Award of the Nobel Prize in Physiology or Medicine

International Stem Cell Corp to Participate in Upcoming Investor Conference

Skinny Nutritional Corp. (SKNY)

The QualityStocks Daily Newsletter would like to spotlight Skinny Nutritional Corp. (SKNY). Today, Skinny Nutritional Corp. closed trading at $0.0018, even with yesterday's close, on 177,312 volume with 10 trades. The stock’s average daily volume over the past 60 days is 1,209,992, and its 52-week low/high is $0.0017/$0.035.

Skinny Nutritional Corp. (SKNY) has established their Skinny Water® brand as a clear alternative to other products in the enhanced water space, with the only true zero calorie, sugar, carb, sodium, and preservative-containing beverage available. Skinny Water's proprietary formulation of essential antioxidant agents, electrolytes, and the critical vitamins our bodies need in order to achieve optimal function, uses 100% natural flavors, no preservatives, no artificial colors, and only the best purified water.

The company has constructed a network of approximately 50 domestic distributors (with three more internationally), placing product on shelves approximately 15k stores across the United States. Derived from the natural flavors contained in fruits, Skinny Water represents a fortified, extremely low-impact, great-tasting array of beverages that provide a concentrated punch of the nutrients essential for a healthier lifestyle.

The company's strong emphasis on health, fitness, and community has served marketing initiatives very well. The new age beverage segment has seen increasing momentum in recent years, with just about every beverage company getting into the game, but none of them has the kind of no-nonsense product composition behind Skinny Water, something that appeals directly to the majority of the core consumer market.

Skinny Nutritional continues to build value around the Skinny Water brand, and today has numerous trademarks in the healthy beverage and snack food categories. As consumers migrate away from sugar based beverages and empty calories, Skinny Water is ideally positioned to benefit from positive market trends as management focuses on delivering exceptional value to shareholders. Disclaimer

Skinny Nutritional Corp. Blog

Skinny Nutritional Corp. News:

Skinny Nutritional Corp. Provides Update on Discussions With Trim Capital

Skinny Nutritional Corp. to Change the Way You Think About Your Water With the Introduction of Skinny Water pH+

A&P's 275 Stores Continue Skinny Water's Mid-Atlantic Penetration

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.70, even for the day, on 500 volume with 1 trade. The stock’s average daily volume over the past 60 days is 699, and its 52-week low/high is $0.06/$3.15.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.

VistaGen's lead drug candidate, AV-101, is in Phase Ib development in the U.S. for treatment of neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system.

Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Therapeutics Completes $3.25 Million Financing and $3.0 Million Debt Restructuring

VistaGen Therapeutics Announces Strategic Financing With Platinum Long Term Growth Fund

VistaGen CEO Issues Update Letter to Stockholders

TNI BioTech, Inc. (TNIB)

The QualityStocks Daily Newsletter would like to spotlight TNI BioTech, Inc. (TNIB). Today, TNI BioTech, Inc. closed trading at $5.04, off by 5.79%, on 12,688 volume with 20 trades. The stock’s average daily volume over the past 60 days is 42,533, and its 52-week low/high is $0.72/$10.01.

TNI BioTech, Inc. (TNIB) is focused on utilizing patented immunotherapy to activate and mobilize the body's immune system to combat fatal diseases. The company's products and technologies improve the treatment and diagnosis of cancer, infections such as HIV/AIDS, and autoimmune diseases. Future initiatives include treatment for multiple sclerosis, herpes viral infections, and other conditions that result in altered-immune response.

The company's product portfolio currently includes IRT-101, an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells; IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells; and IRT-103, an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells.

Leveraging the advantages of today's cutting-edge treatment options, the company aims to meet the growing demand for quality healthcare with safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives around the world. TNI BioTech most recently signed a letter of intent to open clinics in Africa that will provide advanced treatment for cancer, HIV/AIDS, and autoimmune diseases.

The company plans to continue clinical trials in China during 2012 and 2013, and anticipates starting trials in the United States by early 2013.The company is also in negotiations to acquire a number of other immunotherapy products, patents, and therapies. Led by a management team with decades of experience and solid business plan, TNI BioTech is poised to improve healthcare with active and adaptive forms of improved immunotherapies. Disclaimer

TNI BioTech, Inc. Company Blog

TNI BioTech, Inc. News:

TNI BioTech Inc., and Hubei Qianjiang Pharmaceuticals Co., Ltd., Announce Venture Partnership for the Development of New Drug for Cancer Therapies

Dr. Henry "Skip" Lenz, Pharm.D, Joins TNI BioTech, Inc., as Quality Control Officer

TNI BioTech Signs Agreement With Government of Malawi to Open an Oncology & Infectious Disease Clinic at Queen Elizabeth Central Hospital

TNI BioTech, Inc. (TNIB) Capitalizes on Rich Pharmaceutical Experience

TNI BioTech is a leader in the activation and mobilization of the body’s immune system to fight fatal diseases. The company is directed by people who themselves have a history of leadership in the pharmaceutical industry, a fact that has helped the company establish important agreements around the world.

• Nicholas Plotnikoff, Ph.D. (Chairman) has over 20 years in the pharmaceutical industry, specifically in the fields of Pharmacology, Toxicology, and Clinical Research. Dr. Plotnikoff helped develop the immunological effects of MENK. He successfully managed the project teams that developed the N.D.A.’s on Traxene (Valium-like tranquilizer) and Cylert (non-amphetamine psychostimulant). He was the first to identify the central nervous system effects of hypothalamic releasing factors (brain hormones), resulting in clinical development for treatment of depression and Parkinson’s disease. He co-authored 25 publications with Dr. Andrew Schally covering basic research in the field of depression and Parkinson’s disease, and held a number of international patents.

• Dr. Eugene Youkilis, Ph.D. (Director & President) has over 25 years in the pharmaceutical and healthcare industry working in Toxicology, Pharmacology, and Clinical Research. He is a Diplomate of the American Board of Toxicology and former President and Founder of Clinical Bio-Tox Laboratories. He was Laboratory Section Chief and Director at Stroger Hospital (formerly Cook County Hospital), and was a Senior Research Investigator with G. D. Searle and Company. He is currently a Principal Associate with Toxicology Resource Associates, and was a Senior Research Investigator with G. D. Searle and Company.

• Noreen Griffin (Founder & CEO) has played a vital part in the acquisition of patents and therapies involving MENK and LDN, and was involved with the inventors and patent holders for over 5 years before deciding to join the team that formed TNI BioTech, Inc. She has over 25 years of industrial experience, and founded and led a number of startup companies. She has played an integral role in raising multiple rounds of private and venture capital funds on behalf of clients.

• Christopher Pearce (Director & CFO) is one of the founding principals of pH Pharmaceutical, Inc. (a pharmaceutical company focused on the commercial application and licensing of a patented technology) and its affiliated company, pH Solutions. He has over 30 years’ experience as Director and COO of a New York stock exchange listed company with more than 5,000 employees worldwide and $500 million revenue per annum.

• Dr. Ronald Herberman (Sr. VP R&D & Chief Medical Officer) served as the founding director of the University of Pittsburgh Cancer Institute (UPCI) and the UPMC Cancer Center. He was Associate Vice Chancellor for cancer research within the School of Medicine, Department of Health Sciences. Other appointments during his career included Chief of the Division of Hematology/Oncology and the Hillman Professor of Oncology, and Professor of Medicine and Pathology.

• Fengping Shan, Ph.D. (Director & Chief Science Officer) is the Professor of Immunology and Vice Director of the Institute of Immunology, China Medical University, Shenyang, China. He was the Senior Scientist for Penta Biotech and Chief Scientist for the Institute of Microbiological Science and Studies at the Nation Cancer Research in Paris, France. He Shan is an author of 50 Publications and 11 patents.

For additional information, visit www.TNIBiotech.com

BG Medicine, Inc. (BGMD) to Present on Galectin-3 at 2012 American Heart Association Meeting

BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel cardiovascular diagnostics. The company’s first commercial product, the BGM Galectin-3 Test, is for use in patients with heart failure and is available in both the United States and Europe.

The company announced today that it will be launching a major initiative to help hospitals reduce the number of unplanned readmissions for heart failure patients. The initiative will begin at the American Heart Association Scientific Sessions 2012 taking place November 3-7 in Los Angeles. Representatives at the BG Medicine booth (#1737) will be there to highlight the role that Galectin-3 blood testing can play in helping the medical community address the urgent need to reduce hospital readmission rates.

Currently, even with optimal care, nearly a one-fourth of all Medicare heart failure patients are readmitted to the hospital within 30 days. This makes heart failure a major factor of hospital readmission rates, far ahead of heart attack and pneumonia. Because heart failure patients with elevated galectin-3 levels are two-to-three times more likely to be readmitted within 30 days to a hospital, identifying these high risk patients through galectin-3 testing is a potentially valuable and cost-effective in combating these readmissions.

BG Medicine believes the company will benefit and be able to grow the market for its Galectin-3 Test thanks to recent government rulings. Effective October 1, 2012, new rules from the federal Centers for Medicare & Medicaid Services have made reducing unplanned hospital readmissions a critical priority. Hospitals that exceed the Medicare thresholds will be assessed financial penalties that may reach $1 billion by 2015, if improvements are not made.

For additional information about BG Medicine and its Galectin-3 Test, visit www.bg-medicine.com

As Seen On TV, Inc. (ASTV) to Acquire eDiets.com, Inc. (DIET) for $15 Million

As Seen On TV today announced that it will acquire eDiets.com, a provider of personalized nutrition, fitness, and weight-loss programs, in a stock-for-stock transaction valued at approximately $15 million.

The merger is slated to occur during the first quarter of 2013, at which time eDiets.com will become a wholly owned subsidiary of ASTV. eDiets.com will continue to be operated by its current management, which led the company’s achievement of $22 million in revenue over the past 12 months.

ASTV noted synergies between the two companies, as well as their shared vision to accelerate eDiets.com’s food meal delivery business. ASTV CEO Steve Rogai said the merger presents an opportunity to leverage both companies’ offerings to form a stronger entity.

“The decision to merge these companies was a very strategic one. At its core, eDiets is a marketing company that uses direct response to sell their proprietary meal delivery program. Because of this, the opportunity to grow both companies using ASTV’s unique direct response and live shopping channel experience will exponentially grow eDiets and help bring the overall public company to the next level,” Rogai stated in the press release.

Kevin Richardson, chairman of eDiets.com, echoed the sentiment.

“I’m extremely excited about this merger. Both entities bring a lot of experience and success marketing products directly to consumers across a wide range of product categories. A lot of synergies exist between the two companies that I feel will create a powerful direct marketing partnership poised for significant growth in 2013 and beyond,” he stated.

For more information, visit www.eDiets.com or www.TVGoodsInc.com

TeleCommunication Systems, Inc. (TSYS) Announces Opening of New Office in South Africa

TeleCommunication Systems, a world leader in highly reliable and secure mobile communication technology, announced its opening of a new sales office located in Johannesburg, South Africa. The company has stated that this office will act as a focal point for its marketing and sales activities throughout Africa.

“In recent years, we’ve intensified our focus on international expansion, particularly in Africa,” said Jay Whitehurst, senior vice president, Commercial Software Group, TeleCommunication Systems. “By establishing a sales office in Johannesburg, we are able to demonstrate our strong commitment to this key market and provide an opportunity to showcase our location-based services and offer customers competitive platform solutions.”

Additionally, TeleCommunication Systems, as part of its announcement, confirmed that Andy Minnaar has been hired to serve as managing director of the new location. Part of Mr. Minnaar’s responsibilities will include overseeing the operation and sales of the company’s complete line of commercial software solutions, including Location-Based Services (LBS). With more than a decade of communication technology and managerial experience in the African wireless sector, Mr. Minnaar previously worked for Glenayre (acquired by Movius), where he was credited with spearheading the company’s voice messaging business in Africa, a move that made Movius the preferred voice messaging partner to the largest network operator on the continent.

“A logical next step for TeleCommunication Systems is to expand our activity into the African market, and we have asked Andy Minnaar to lead our efforts in that region. Andy has a strong background in the African mobile telecommunications industry and is a seasoned executive with a passion for innovation and finding the right solutions for customers,” stated Brian McNealy, senior vice president, global commercial sales, TeleCommunication Systems, Inc. ” His experience will serve us well as we continue to expand our wireless solutions and platforms offerings into international markets.”

TeleCommunication Systems has become a world-wide industry leader in high-reliability location-based services. Furthermore, the company provides complete, end-to-end wireless LBS solutions, including both branded and private-label applications, infrastructure, mapping, and content for leading consumer brands, content providers, and voice service providers worldwide. In addition to being the industry’s leading provider of LBS infrastructure, TeleCommunication Systems also provided the world’s first wireless location platform.

For more information, visit www.telecomsys.com


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters








By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors

The QualityStocks By The Numbers Report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251